Advanced search
1 file | 101.30 KB

Catechol-O-methyltranferase gene expression is associated with response to citalopram in obsessive-compulsive disorder

Author
Organization
Abstract
Objective. To determine whether polymorphisms of the dopamine D-2 receptor (DRD2) and catechol-O-methyl-transferase (COMT) receptor genes affect the efficacy of quetiapine addition to citalopram in patients with OCD. Methods. Sixty-four drug-free or drug-naive patients meeting DSM-IV criteria for OCD were randomized to 10 weeks double-blind treatment with citalopram (60 mg/day) with quetiapine (300-450 mg/day) or with placebo. The change from baseline to endpoint on the total Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) and the response to treatment were the primary outcome measures. Response was defined as a 25% decrease in Y-BOCS score. Responders and nonresponders were stratified according to DRD2 TaqI A and COMT Val(158)Met genotypes. Results. No significant differences in genotype distribution or allele frequencies of the COMT or DRD2 receptor were found between responders and nonresponders to citalopram with quetiapine. However, nearly half of responders to citalopram with placebo carried the Met/Met (48%) genotype of the COMT polymorphism compared to none of the nonresponders (chi(2) = 10.06, df = 2, P = 0.007). Conclusions. The Met allele load of the COMT receptor gene was associated with response to 10 weeks of treatment with citalopram in drug-free or drug-naive OCD patients.
Keywords
NAIVE PATIENTS, HUMAN BRAIN, ANTIPSYCHOTIC AGENTS, SEROTONERGIC MODULATION, RECEPTOR-BINDING, MAJOR DEPRESSION, ANTIDEPRESSANT DRUGS, DOPAMINE TRANSPORTER DENSITY, POSITRON-EMISSION-TOMOGRAPHY, treatment, citalopram, genes, RAT PREFRONTAL CORTEX, catechol-O-methyltranferase, Obsessive-compulsive disorder

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 101.30 KB

Citation

Please use this url to cite or link to this publication:

Chicago
Vulink, Nienke CC, Herman GM Westenberg, Filip Van Nieuwerburgh, Dieter Deforce, Sjoerd BAHA Fluitman, Jantien SC Meinardi, and Damiaan Denys. 2012. “Catechol-O-methyltranferase Gene Expression Is Associated with Response to Citalopram in Obsessive-compulsive Disorder.” International Journal of Psychiatry in Clinical Practice 16 (4): 277–283.
APA
Vulink, N. C., Westenberg, H. G., Van Nieuwerburgh, F., Deforce, D., Fluitman, S. B., Meinardi, J. S., & Denys, D. (2012). Catechol-O-methyltranferase gene expression is associated with response to citalopram in obsessive-compulsive disorder. INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE, 16(4), 277–283.
Vancouver
1.
Vulink NC, Westenberg HG, Van Nieuwerburgh F, Deforce D, Fluitman SB, Meinardi JS, et al. Catechol-O-methyltranferase gene expression is associated with response to citalopram in obsessive-compulsive disorder. INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE. 2012;16(4):277–83.
MLA
Vulink, Nienke CC, Herman GM Westenberg, Filip Van Nieuwerburgh, et al. “Catechol-O-methyltranferase Gene Expression Is Associated with Response to Citalopram in Obsessive-compulsive Disorder.” INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE 16.4 (2012): 277–283. Print.
@article{3095008,
  abstract     = {Objective. To determine whether polymorphisms of the dopamine D-2 receptor (DRD2) and catechol-O-methyl-transferase (COMT) receptor genes affect the efficacy of quetiapine addition to citalopram in patients with OCD.
Methods. Sixty-four drug-free or drug-naive patients meeting DSM-IV criteria for OCD were randomized to 10 weeks double-blind treatment with citalopram (60 mg/day) with quetiapine (300-450 mg/day) or with placebo. The change from baseline to endpoint on the total Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) and the response to treatment were the primary outcome measures. Response was defined as a 25\% decrease in Y-BOCS score. Responders and nonresponders were stratified according to DRD2 TaqI A and COMT Val(158)Met genotypes.
Results. No significant differences in genotype distribution or allele frequencies of the COMT or DRD2 receptor were found between responders and nonresponders to citalopram with quetiapine. However, nearly half of responders to citalopram with placebo carried the Met/Met (48\%) genotype of the COMT polymorphism compared to none of the nonresponders (chi(2) = 10.06, df = 2, P = 0.007).
Conclusions. The Met allele load of the COMT receptor gene was associated with response to 10 weeks of treatment with citalopram in drug-free or drug-naive OCD patients.},
  author       = {Vulink, Nienke CC and Westenberg, Herman GM and Van Nieuwerburgh, Filip and Deforce, Dieter and Fluitman, Sjoerd BAHA and Meinardi, Jantien SC and Denys, Damiaan},
  issn         = {1365-1501},
  journal      = {INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE},
  language     = {eng},
  number       = {4},
  pages        = {277--283},
  title        = {Catechol-O-methyltranferase gene expression is associated with response to citalopram in obsessive-compulsive disorder},
  url          = {http://dx.doi.org/10.3109/13651501.2011.653375},
  volume       = {16},
  year         = {2012},
}

Altmetric
View in Altmetric
Web of Science
Times cited: